Technical Analysis for ARDS - Aridis Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 7.71 -3.99% -0.32
ARDS closed down 3.99 percent on Thursday, August 22, 2019, on 4 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ARDS trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -3.99%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.99%
Wide Bands Range Expansion -3.99%
Gapped Up Strength -3.99%
Oversold Stochastic Weakness -3.99%
1,2,3 Retracement Bearish Bearish Swing Setup 0.78%
Boomer Sell Setup Bearish Swing Setup 0.78%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.78%
Narrow Range Bar Range Contraction 0.78%

Older signals for ARDS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.
Medicine Biopharmaceutical Medical Specialties Infectious Diseases Antibodies Immunotherapy Monoclonal Antibody Bacterial Infections Infections Healthcare Associated Infections Bacterial Diseases Pathogenic Bacteria Pneumonia Pseudomonas Aeruginosa Targeted Immunotherapy
Is ARDS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.85
52 Week Low 6.915
Average Volume 4,656
200-Day Moving Average 9.7361
50-Day Moving Average 9.1499
20-Day Moving Average 8.4193
10-Day Moving Average 8.0285
Average True Range 0.5198
ADX 35.23
+DI 13.5563
-DI 30.4825
Chandelier Exit (Long, 3 ATRs ) 8.7105
Chandelier Exit (Short, 3 ATRs ) 9.0694
Upper Bollinger Band 9.8013
Lower Bollinger Band 7.0373
Percent B (%b) 0.24
BandWidth 32.829333
MACD Line -0.4601
MACD Signal Line -0.4289
MACD Histogram -0.0312
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.71
Resistance 3 (R3) 7.71 7.71 7.71
Resistance 2 (R2) 7.71 7.71 7.71 7.71
Resistance 1 (R1) 7.71 7.71 7.71 7.71 7.71
Pivot Point 7.71 7.71 7.71 7.71 7.71
Support 1 (S1) 7.71 7.71 7.71 7.71 7.71
Support 2 (S2) 7.71 7.71 7.71 7.71
Support 3 (S3) 7.71 7.71 7.71
Support 4 (S4) 7.71